FDA Grants Orphan Drug Designation to PYX-201 in Pancreatic Cancer

0
268
The FDA has granted an orphan drug designation for PYX-201 to continue its development as a treatment for patients with pancreatic cancer.
[Pyxis Oncology, Inc. (Targeted Oncology)]
Press Release